“That, for me, personally, was one of those watershed moments. Okay, this is going to happen.” - Innovative Genomics Institute founder and #CRISPR pioneer Jennifer Doudna in conversation with Sarah Zhang at The Atlantic who goes on to write: "And now, it has happened. Gray and patients like her are living proof of gene-editing power. Sickle-cell disease is the first disease—and unlikely the last—to be transformed by CRISPR." For more, read the excellent article aptly titled "The CRISPR Era Is Here": https://lnkd.in/gkjhynkj
Thermal’s Post
More Relevant Posts
-
Looking to work with the world’s leading scientists and #healthtech companies? Check out #PR career opportunities at Thermal and join the team providing award-winning counsel to the visionaries building a new era of healthcare. https://lnkd.in/eUGmTgi #hiring #publicrelations #healthcarepr #healthtech #health #digitalhealth
-
Congrats to Andrea Choe and the Holoclara Inc team! 👏
We’re excited to announce the completion of our oversubscribed Series A financing to advance first-in-class, worm-derived therapies for allergic and autoimmune disease into the clinic later this year. We are proud to be backed by leading life sciences and technology investors including BOLD Capital Partners, Horizons Ventures, Tarrasque, Endurance28, K5 Global, Freeflow Ventures, and a syndicate of angel investors. Our discovery engine technology builds on our co-founder and CEO Andrea Choe’s discovery out of Caltech of a unique pheromone language shared by roundworms and molecules derived from these worms that block disease formation. We are uniquely capable of mining these potent immunomodulatory molecules, paving a way for novel nature-inspired medicines to address historically untreatable diseases and transform the lives of millions of patients. Learn more about our work in the following video and links: Press release: https://lnkd.in/geryCtbw Fortune article: https://lnkd.in/grgMtfFV Our website: https://www.holoclara.com/ #Worms #WormScience #WormTherapies #Allergies #Autoimmune #Biotech
-
Congrats to the TwoStep Therapeutics team! 👏
We’re excited to announce our official launch and the closing of a $6.5M seed round to advance our pipeline of targeted therapies for solid tumors. Our delivery platform is built around a unique tumor-targeting agent that can selectively bind five targets that are highly expressed on solid tumors. This multi-targeting feature enables broad applicability across a wide range of tumor types and patient populations, overcoming the limitations of traditional single-antigen targeting approaches. Led by co-founder and CEO Caitlyn Miller, PhD, our mission is to revolutionize cancer care by developing precise, effective, and broadly applicable targeted therapies. Our work is guided by world-class academic-entrepreneurs at Stanford, including co-founders Carolyn Bertozzi, Jennifer Cochran and Ron Levy. We launched from the Stanford University Innovative Medicines Accelerator (IMA) and are backed by a syndicate of high quality investors, led by NFX with participation from 2048 Ventures, Alexandria Real Estate Equities, Inc., Cooley LLP’s affiliated fund GC&H Investments, and the family office of the founder of Arcadia Investment Partners. Read the full press release to learn more: Press Release: https://lnkd.in/gErBpaBg Endpoints article: https://lnkd.in/gx_4paV3 Company website: www.twosteptx.com
-
Senior Science Writer | Bridging Research and Public Understanding of Science
6moFantastic read, thank you for sharing Kaustuva.